HOME >> BIOLOGY >> NEWS
Crystal structure for anthrax-cell binding complex

NOTE: This paper is being pulished early in an online edition.

(La Jolla, CA). A team of researchers led by The Burnham Institute's Robert C. Liddington has determined the crystal structure of the binding complex between anthrax toxin and one of its host receptors. Inhalation anthrax, unless diagnosed at a very early stage, is fatal: there is no existing antidote once the toxin is blood borne. The studies published by Liddington and colleagues on-line in the July 4th issue of Nature offer new leads for the discovery of anthrax antitoxins that could be used in conjunction with antibiotics to treat late-stage anthrax. In a surprising twist, the new information will also help in the design of anthrax toxin as an anti-tumor agent for treatment of cancer.

Anthrax toxin is comprised of three proteins: protective antigen (PA), lethal factor (LF), and edema factor (EF). To gain entry into host cells, PA must recognize a receptor on the surface of the target cell. Once PA has bound to the cell, it then enables EF and LF to bind and form a pore through which PA forces EF and LF into the cell in a syringe-like action.

Liddington's laboratory, together with Stephen Leppla at the National Institute of Allergy and Infectious Diseases, studied the interaction of PA with the two known receptors for anthrax: TEM8 and CMG2. PA binds tightly to both receptors and can use either to transfer toxicity into the cell. They were able to determine the crystal structure of the PA-CMG2 binding complex at atomic resolution, which makes it possible to design small molecules that will interact with PA and prevent the binding complex from forming. Soluble forms of the receptors have indeed acted as decoys, distracting PA from binding both receptors.

The two receptors are similar in how they mediate entry into the cells, but differ in important ways: The CMG2 receptor is present in most tissues, whereas the TEM8 receptor is mostly found on the
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-449-9940
Burnham Institute
4-Jul-2004


Page: 1 2

Related biology news :

1. Crystallographers take note: A synchrotron light source for your home lab
2. Crystal engineering helps scientists solve 3-D protein structures
3. Crystal structure of protein interaction could lead to new drugs against cancer
4. NYU Researchers Develop Simple, Predictable And Precise Technique For Arranging DNA Molecules Into Two-Dimensional Crystals
5. Crystal Structure Of Key HIV Protein Reveals New Treatment Targets
6. Space Grown Insulin Crystals Provide New Data On Diabetes
7. Biochemists Gain Crystal-Clear Insight into Ancient Enzyme
8. Crystal Structure Of The Archaeal Chaperonin Thermosome, A Protein-Folding Machine, Determined
9. Liquid Crystals Light Up Simple Chemical Test
10. DNA Enzyme Works In Crystal Form; Yields New Insights Into Gene Copying
11. Scientists Determine 3-D Crystal Structure Of Cancer-Causing Protein

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Crystal structure for anthrax cell binding complex

(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
(Date:2/26/2015)... 26, 2015 Regis Technologies announced ... of oncology drug substances. , Regis Technologies is proud ... new Potent Compound Suite (PCS) for 2015. , Regis ... foot, cGMP facility in Morton Grove, Illinois. The PCS ... potent compounds up to about one kilogram per batch. ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
Cached News: